Dr Kate Ahmad
Royal North Shore Hospital
Drug Treatment In Patients With OPA1 Related Dominant Optic Atrophy Plus
Dr Ahmad and Professor Carolyn Sue will conduct a pilot clinical trial investigating a potential therapy for patients with Dominant Optic Atrophy and Dominant Optic Atrophy Plus as a result of OPA1 mutations. Dominant Optic Atrophy is a mitochondrial disorder and causes visual loss, often beginning in childhood. It can cause additional neurological signs such as deafness, ataxia and peripheral neuropathy. This is one of the first therapeutic clinical trials to take place in Australia in the field of mitochondrial research.
There is an opportunity for suitable patients to be included in this trial. If you are known or suspected to have Dominant Optic Atrophy, then please contact Services Officer Tim Burchell for further information on 02 8033 4113 or email email@example.com